333 related articles for article (PubMed ID: 24522741)
1. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.
Hocking CM; Kichenadasse G
Support Care Cancer; 2014 Apr; 22(4):1143-51. PubMed ID: 24522741
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
Wang XF; Feng Y; Chen Y; Gao BL; Han BH
Sci Rep; 2014 Apr; 4():4813. PubMed ID: 24770591
[TBL] [Abstract][Full Text] [Related]
3. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Bosnjak SM; Dimitrijevic J; Djordjevic F
Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
[TBL] [Abstract][Full Text] [Related]
4. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Meena JP; Gupta AK; Jat KR; Anandani G; Sasidharan A; Tanwar P
J Pediatr Hematol Oncol; 2023 Oct; 45(7):361-369. PubMed ID: 37539996
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C
Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
Chiu L; Chow R; Popovic M; Navari RM; Shumway NM; Chiu N; Lam H; Milakovic M; Pasetka M; Vuong S; Chow E; DeAngelis C
Support Care Cancer; 2016 May; 24(5):2381-2392. PubMed ID: 26768437
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
Yoodee J; Permsuwan U; Nimworapan M
Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253
[TBL] [Abstract][Full Text] [Related]
10. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Tan L; Liu J; Liu X; Chen J; Yan Z; Yang H; Zhang D
J Exp Clin Cancer Res; 2009 Sep; 28(1):131. PubMed ID: 19775450
[TBL] [Abstract][Full Text] [Related]
11. Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.
DeRemer DL; Clemmons AB; Orr J; Clark SM; Gandhi AS
Pharmacotherapy; 2016 Feb; 36(2):218-29. PubMed ID: 26890915
[TBL] [Abstract][Full Text] [Related]
12. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Navari RM; Nagy CK; Gray SE
Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.
Alhifany AA; McBride A; Almutairi AR; Cheema E; Shahbar A; Alatawi Y; Alharbi AS; Babiker H; MacDonald K; Aapro M; Abraham I
Support Care Cancer; 2020 Mar; 28(3):1031-1039. PubMed ID: 31823054
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting.
Navari RM
Biomed Res Int; 2015; 2015():595894. PubMed ID: 26421294
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
Wang SY; Yang ZJ; Zhang L
Asian Pac J Cancer Prev; 2014; 15(22):9587-92. PubMed ID: 25520071
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials.
Zhou JG; Huang L; Jin SH; Xu C; Frey B; Ma H; Gaipl US
ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079622
[TBL] [Abstract][Full Text] [Related]
19. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.
Chanthawong S; Lim YH; Subongkot S; Chan A; Andalusia R; Ahmad Bustamam RS; Chaiyakunapruk N
Support Care Cancer; 2019 Mar; 27(3):1109-1119. PubMed ID: 30112718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
